Top Markets
#1 Wrapped STX (Velar) Wrapped STX (Velar) +45.25%
#2 Mubarak Mubarak +42.17%
#3 Pons Pons +38.98%
#4 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +29.88%
#5 Starpower Starpower +28.91%
#6 Bitway Bitway +25.89%
#7 SkyAI SkyAI +24.04%
#8 TENDIES TENDIES +22.47%
#9 StonkBroker StonkBroker +20.76%
#10 Decred Decred +20.59%
Coin of the day
Wrapped STX (Velar) Wrapped STX (Velar)
Tetapan
Bahasa
MALAY
Mata wang
USD
Tema
ABVC BioPharma, Inc. ABVC BioPharma, Inc.

ABVC BioPharma, Inc.

ABVC
Kedudukan dalam Saham #28867
ABVC BioPharma, Inc. is a clinical-stage biopharmaceutical company focused on... ABVC BioPharma, Inc. is a clinical-stage biopharmaceutical company focused on creating novel drugs and medical devices to address critical, underserved healthcare requirements across the United States. The company's pipeline includes several key candidates: ABV-1501, currently undergoing Phase I/II clinical trials, is being developed as a combination treatment for triple-negative breast cancer. ABV-1504 has successfully completed Phase II clinical trials for major depressive disorders. ABV-1505 is progressing through Phase II clinical studies for attention deficit hyperactivity disorder (ADHD). ABV-1703 has concluded its Phase I clinical trials for the treatment of pancreatic cancer. ABV-1702 has also finished Phase I clinical investigations for myelodysplastic syndromes. ABV-1601 is in Phase I/II clinical trials, aimed at alleviating depression in individuals with cancer. ABV-1701 Vitargus is in development to treat conditions such as retinal detachment or vitreous hemorrhage. ABVC BioPharma maintains strategic alliances, including a co-development arrangement with Rgene Corporation, alongside collaborative agreements with BioHopeKing Corporation and BioFirst Corporation. The company's headquarters are located in Fremont, California, and it operates as a subsidiary of YuanGene Corporation.
Harga Saham
$0.9201
Modal Pasaran
$23.92M
Perubahan (1 hari)
6.23%
Perubahan (1 tahun)
-67.72%
Negara
US
Perdagangan ABVC BioPharma, Inc. (ABVC)

Kategori

Healthcare
Nisbah P/E bagi ABVC BioPharma, Inc. (ABVC)
Nisbah P/E pada 2026 TTM: 0
Menurut laporan kewangan dan harga saham terkini ABVC BioPharma, Inc., nisbah P/E semasa (TTM) ialah 0. Pada akhir 2026, syarikat mempunyai nisbah P/E sebanyak 0.
Sejarah nisbah P/E bagi ABVC BioPharma, Inc. dari 2026 hingga 2026
Nisbah P/E pada akhir setiap tahun
Tahun Nisbah P/E Ubah
Tidak cukup data untuk tarikh yang disediakan.
Nisbah P/E untuk syarikat serupa atau pesaing
Syarikat Nisbah P/E Perbezaan Nisbah P/E Negara
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 29.20 -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 30.62 -
NL
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 -7.93 -
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
 32.46 -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Cara membaca nisbah P/E

Nisbah Harga/Perolehan (P/E) mengukur hubungan antara harga saham syarikat dan pendapatan sesaham.
P/E yang rendah tetapi positif menunjukkan syarikat menjana keuntungan tinggi berbanding dengan penilaian semasa dan mungkin dinilai rendah. P/E negatif yang tinggi (hampir 0) menunjukkan kerugian besar.

Syarikat dengan P/E melebihi 30 atau negatif biasanya dilihat sebagai "saham pertumbuhan", bermaksud pelabur menjangkakan pertumbuhan atau keuntungan masa depan.

Syarikat dengan P/E positif di bawah 10 biasanya dianggap sebagai "saham nilai", bermaksud syarikat sudah menguntungkan dan tidak dijangka berkembang pesat.